Amphastar Pharmaceuticals, Inc.
NASDAQAmphastar Pharmaceuticals heads into early summer with a badly damaged chart, a crowded short book, and a Street that has turned firmly against the name — all in the wake of a catastrophic Q1 print. The short interest story is the defining dynamic right now. Bears have rebuilt aggressively since the May 7 earnings implosion, and short interest has climbed back toward cycle highs…
Snapshot as of 3 Jun 2026
Amphastar Pharmaceuticals heads into early summer with a badly damaged chart, a crowded short book, and a Street that has turned firmly against the name — all in the wake of a catastrophic Q1 print. The short interest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AMPH — free to start on ORTEX.
Sign up for free →Open AMPH on ORTEX